Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study – Biological Phase (EPHOS-B). The EPHOS-B trial is a multicentre, three group, randomised controlled trial conducted in two parts. Part 1 (protocol versions 1 to 4): HER2+ patients were allocated in a 1:2:2 ratio to control, perioperative trastuzumab only or perioperative lapatinib only. This part of the trial will be superseded by Part 2 following the approval of amendment 5 by West Midlands - Edgbaston NRES Committee on 15/05/2013 and subsequently in each centre. Part 2 (Implemented from protocol version 5): HER2+ patients are allocated in a 1:1:2 ratio to control, perioperative trastuzumab only or the combination of lapatinib and trastuzumab. This part is now active.
- ICR Clinical Trials & Statistics Unit (ICR-CTSU) ICR-CTSU is a research-led, academic clinical trials unit (CTU) within the Division of Clinical Studies at the ICR. Our expertise spans the whole clinical trial life cycle. We receive core funding from Cancer Research UK, are a UK Clinical Research Collaborative (UKCRC) registered CTU and one of 15 CTUs recognised by the National Cancer Research Institute (NCRI) for professional specialism in the development and delivery of cancer trials. ICR-CTSU is committed to the responsible sharing of clinical trial data and trial samples with the wider research community in order to improve scientific and medical knowledge about cancer. To enable data and samples to be effectively shared with others, an access policy and defined procedure exist to ensure that relevant legal, ethical and commercial constraints are recognised and that data and samples are made available for new research purposes in a responsible manner. Please consult the data sharing page for further information.
The Institute of Cancer Research
15 Cotswold Road
|Year||Access Requests Received||Access Requests Approved|